Replies to post #1412 on Acadia Pharmaceuticals Inc. (ACAD)

[rogerm]

I was lucky to start buying shortly after you put ACAD on your watch list. Pimavanserin is unique in that it selectively blocks just the 5ht2a receptor. That allows for fewer side effects in a world that has been turning against the current antipsychotics which hit 5HT2A but also a bunch of other targets that increase weight, diabetes, cognitive impairment and mortality. I expect ACAD's price to reach $40 later this year after Pima's NDA has been submitted to the FDA. ACAD owns 100% of Pima, has no debt and will have >$300 million in the bank after this stock offering.

[dubbya]

I bought in the Fall of 2012 and am in no rush to sell. Like they say, "Let your winners run". I'll sell somewhere over $40- where many finally see it as more than a "spec play", LOL...

But seriously, I want to stick around to see how it does treating Alzheimer's too. That could add another major chunk to it.